Inmed Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 4.2% of InMed Pharmaceuticals Inc. common shares, totaling 137,634 shares.
NASDAQ
ADAR1 Capital Management and Daniel Schneeberger have reported a 24.1% beneficial ownership stake in InMed Pharmaceuticals, Inc.
NASDAQ
Squadron Master Fund LP, along with its affiliates, has disclosed beneficial ownership of 325,000 shares, representing 9.8% of InMed Pharmaceuticals Inc.'s common stock.
NASDAQ
Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have disclosed a 9.9% beneficial ownership stake in InMed Pharmaceuticals Inc.
NASDAQ
SCHEDULE 13G/A: AdvisorShares Trust Divests Entire Stake in InMed Pharmaceuticals, Files Amended 13G
AdvisorShares Trust has filed an amended Schedule 13G, disclosing that it no longer holds any beneficial ownership in InMed Pharmaceuticals Inc.
NASDAQ
Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly reported a passive beneficial ownership of 4.9% in InMed Pharmaceuticals Inc.'s common stock as of December 31, 2024.